Cardiff Oncology, Inc. (NASDAQ: CRDF) Chief Executive Officer Mani Mohindru executed a significant insider transaction on July 14, 2026, acquiring 34,364 shares of the company's common stock. The shares were purchased at a price of $1.455 per share, resulting in a total investment of $49,999. This acquisition occurs as Cardiff Oncology's stock trades at approximately $0.88, representing a 33% decline over the past week and hovering near its 52-week low of $0.83.
On the same date, Mohindru also acquired 34,364 common stock purchase warrants. These warrants carry a conversion or exercise price of $1.33 per share. The warrants become exercisable on the later of six months after issuance or the "Authorized Share Increase Date," which is defined as the date an amendment to the Issuer's certificate of incorporation, increasing the number of authorized shares of its common stock, is filed and accepted by the State of Delaware, subject to approval of such amendment by its stockholders. The term of exercise for these warrants is five and one-half years after their initial exercise date.
Following these transactions, Mohindru directly holds 59,067 shares of Cardiff Oncology common stock, in addition to the 34,364 common stock purchase warrants. According to InvestingPro analysis, the stock appears undervalued at current levels. Investors seeking deeper insights can access comprehensive Pro Research Reports, available for Cardiff Oncology and 1,400+ other US equities on InvestingPro.
In other recent news, Cardiff Oncology announced a $10 million registered direct offering, selling 8,571,429 shares of common stock and accompanying warrants at $1.05 per share. Company officers and directors are participating in this offering, purchasing shares at a slightly higher price of $1.435 per share. The warrants will become exercisable six months after issuance or upon stockholder approval to increase authorized shares.
Additionally, Cardiff Oncology reported positive results from its Phase 2 clinical trial of onvansertib, which were presented at the 2026 American Society of Clinical Oncology Annual Meeting. However, the company is facing challenges as H.C. Wainwright downgraded its stock rating to Neutral following the termination of a key license agreement with Nerviano Medical Sciences. TD Cowen also downgraded Cardiff Oncology to Hold due to a licensing dispute over onvansertib. In light of these developments, Cardiff Oncology plans to host an investor webcast to discuss updated data from its clinical trial.